| 2019-11-29 |
TLC to Hold Investor Conference in Taipei |
|
| 2019-11-27 |
TLC Announces First Patient Enrollment in EXCELLENCE Trial Evaluating Single and Repeat Administrations of TLC599 |
|
| 2019-11-12 |
TLC to Present at Berenberg Pain Seminar |
|
| 2019-10-24 |
TLC Announces Completion of US$27 Million Financing |
|
| 2019-10-22 |
TLC Reports Third Quarter 2019 Financial Results and Provides Business Update |
|
| 2019-10-21 |
TLC Presents Clinical and Preclinical Data of TLC590 at ANESTHESIOLOGY® Annual Meeting and in International Journal of Nanomedicine |
|
| 2019-10-20 |
TLC Appoints Vincent Chang, PhD, as Vice President of Manufacturing Development |
|
| 2019-10-07 |
TLC to Present Potential Cartilage-Protecting Effects of TLC599 on the Knee at 2019 ACR Annual Meeting |
|
| 2019-10-01 |
TLC Announces Initiation of Phase III Pivotal Clinical Trial of TLC599 for the Treatment of Osteoarthritis Knee Pain |
|
| 2019-09-23 |
TLC to Present Preclinical Data on TLC178 at ESMO 2019 |
|
| 2019-09-03 |
TLC to Present as Panelist among Key Opinion Leaders at the BTIG Pain Management Forum |
|
| 2019-08-28 |
TLC to Present at Upcoming Investor Conferences in September 2019 |
|
| 2019-07-30 |
TLC Reports Second Quarter 2019 Financial Results and Provides Business Update |
|
| 2019-06-25 |
TLC Announces Development and License Agreement with Birdie Biopharmaceuticals for NanoX™ Immunotherapy Product |
|
| 2019-06-14 |
TLC Announces Part 1 Analysis of TLC590 Phase II Clinical Trial for Postsurgical Pain Management following Bunionectomy |
|
| 2019-06-12 |
TLC Presents New Pharmacokinetic and Toxicokinetic Data on TLC599 Following Intra-articular Injection in Dogs at EULAR 2019 |
|
| 2019-05-08 |
TLC Reports First Quarter of 2019 Financial Results and Provides Business Update |
|
| 2019-05-06 |
TLC Highlights Data Presentations on Lead Product Candidate TLC599 at Osteoarthritis Research Society International (OARSI) 2019 World Congress |
|
| 2019-05-02 |
TLC Earns Highest Ranks in Corporate Governance Evaluation for 5th Consecutive Year |
|
| 2019-04-22 |
TLC to Present at Upcoming Conferences |
|
| 2019-04-15 |
TLC Announces Positive End-of-Phase II Meeting with FDA for TLC599 in Knee Osteoarthritis |
|
| 2019-04-08 |
TLC Announces Full Enrollment in Part 1 of Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy |
|
| 2019-04-01 |
TLC Reports Fourth Quarter and Full Year 2018 Financial Results and Business Update |
|
| 2019-03-25 |
TLC to Present High-Scoring Scientific Abstracts on Acute Pain through Moderated Sessions at ASRA Spring 2019 |
|
| 2019-03-18 |
TLC Announces First Patient Dosed in Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy |
|
| 2019-03-11 |
TLC Reports Positive Top-Line Results from Phase I/II Clinical Trial of TLC590 for Postsurgical Pain |
|
| 2019-03-03 |
TLC and 3SBio Form Exclusive Partnership to Commercialize Two NanoX™ Products in Mainland China |
|
| 2019-01-25 |
TLC Appoints George Spencer-Green, MD, MS, as Chief Medical Officer |
|
| 2019-01-22 |
EMA Grants Orphan Drug Designation to TLC178 for the Treatment of Soft Tissue Sarcoma |
|
| 2019-01-02 |
Taiwan Liposome Company to Attend 37th Annual J.P. Morgan Healthcare conference |
|
